EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...

A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.

The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...

AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion recommending the ...

(RTTNews) - AbbVie (ABBV) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Upadacitinib combined with topical corticosteroids led to rapid and lasting relief from atopic dermatitis (AD ...

AbbVie said it anticipates a regulatory decision on upadacitinib from the FDA in Q3 2019. The drug is also under review by the European Medicines Agency for the treatment of adult patients with ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

The final European Commission decision is expected in the first half of 2025. If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA. "Giant cell ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...